333 related articles for article (PubMed ID: 12498714)
1. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis.
Moody SE; Sarkisian CJ; Hahn KT; Gunther EJ; Pickup S; Dugan KD; Innocent N; Cardiff RD; Schnall MD; Chodosh LA
Cancer Cell; 2002 Dec; 2(6):451-61. PubMed ID: 12498714
[TBL] [Abstract][Full Text] [Related]
2. Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice.
Maroulakou IG; Oemler W; Naber SP; Tsichlis PN
Cancer Res; 2007 Jan; 67(1):167-77. PubMed ID: 17210696
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo antisense-mediated growth inhibition of a mammary adenocarcinoma from MMTV-neu transgenic mice.
Sacco MG; Barbieri O; Piccini D; Noviello E; Zoppé M; Zucchi I; Frattini A; Villa A; Vezzoni P
Gene Ther; 1998 Mar; 5(3):388-93. PubMed ID: 9614559
[TBL] [Abstract][Full Text] [Related]
4. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene.
Muller WJ; Sinn E; Pattengale PK; Wallace R; Leder P
Cell; 1988 Jul; 54(1):105-15. PubMed ID: 2898299
[TBL] [Abstract][Full Text] [Related]
5. Expression of the calcium-binding protein S100A4 (p9Ka) in MMTV-neu transgenic mice induces metastasis of mammary tumours.
Davies MP; Rudland PS; Robertson L; Parry EW; Jolicoeur P; Barraclough R
Oncogene; 1996 Oct; 13(8):1631-7. PubMed ID: 8895508
[TBL] [Abstract][Full Text] [Related]
6. Inducible and coupled expression of the polyomavirus middle T antigen and Cre recombinase in transgenic mice: an in vivo model for synthetic viability in mammary tumour progression.
Rao T; Ranger JJ; Smith HW; Lam SH; Chodosh L; Muller WJ
Breast Cancer Res; 2014 Jan; 16(1):R11. PubMed ID: 24457046
[TBL] [Abstract][Full Text] [Related]
7. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
8. Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice.
Muller WJ; Arteaga CL; Muthuswamy SK; Siegel PM; Webster MA; Cardiff RD; Meise KS; Li F; Halter SA; Coffey RJ
Mol Cell Biol; 1996 Oct; 16(10):5726-36. PubMed ID: 8816486
[TBL] [Abstract][Full Text] [Related]
9. Sustained trophism of the mammary gland is sufficient to accelerate and synchronize development of ErbB2/Neu-induced tumors.
Landis MD; Seachrist DD; Abdul-Karim FW; Keri RA
Oncogene; 2006 Jun; 25(23):3325-34. PubMed ID: 16434967
[TBL] [Abstract][Full Text] [Related]
10. PEA3 is overexpressed in mouse metastatic mammary adenocarcinomas.
Trimble MS; Xin JH; Guy CT; Muller WJ; Hassell JA
Oncogene; 1993 Nov; 8(11):3037-42. PubMed ID: 7692372
[TBL] [Abstract][Full Text] [Related]
11. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease.
Guy CT; Webster MA; Schaller M; Parsons TJ; Cardiff RD; Muller WJ
Proc Natl Acad Sci U S A; 1992 Nov; 89(22):10578-82. PubMed ID: 1359541
[TBL] [Abstract][Full Text] [Related]
12. Evolution of somatic mutations in mammary tumors in transgenic mice is influenced by the inherited genotype.
Podsypanina K; Li Y; Varmus HE
BMC Med; 2004 Jun; 2():24. PubMed ID: 15198801
[TBL] [Abstract][Full Text] [Related]
13. A mouse transgenic approach to induce β-catenin signaling in a temporally controlled manner.
Mukherjee A; Soyal SM; Li J; Ying Y; Szwarc MM; He B; Kommagani R; Hodgson MC; Hiremath M; Cowin P; Lydon JP
Transgenic Res; 2011 Aug; 20(4):827-40. PubMed ID: 21120693
[TBL] [Abstract][Full Text] [Related]
14. Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis.
Gunther EJ; Moody SE; Belka GK; Hahn KT; Innocent N; Dugan KD; Cardiff RD; Chodosh LA
Genes Dev; 2003 Feb; 17(4):488-501. PubMed ID: 12600942
[TBL] [Abstract][Full Text] [Related]
15. Activated neu induces rapid tumor progression.
Guy CT; Cardiff RD; Muller WJ
J Biol Chem; 1996 Mar; 271(13):7673-8. PubMed ID: 8631805
[TBL] [Abstract][Full Text] [Related]
16. The matrix metalloproteinase matrilysin influences early-stage mammary tumorigenesis.
Rudolph-Owen LA; Chan R; Muller WJ; Matrisian LM
Cancer Res; 1998 Dec; 58(23):5500-6. PubMed ID: 9850086
[TBL] [Abstract][Full Text] [Related]
17. Vitamin D receptor status alters mammary gland morphology and tumorigenesis in MMTV-neu mice.
Zinser GM; Welsh J
Carcinogenesis; 2004 Dec; 25(12):2361-72. PubMed ID: 15333467
[TBL] [Abstract][Full Text] [Related]
18. A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology.
Gunther EJ; Belka GK; Wertheim GB; Wang J; Hartman JL; Boxer RB; Chodosh LA
FASEB J; 2002 Mar; 16(3):283-92. PubMed ID: 11874978
[TBL] [Abstract][Full Text] [Related]
19. Changes associated with delay of mammary cancer by retinoid analogues in transgenic mice bearing c-neu oncogene.
Rao GN; Ney E; Herbert RA
Breast Cancer Res Treat; 1999 Dec; 58(3):241-54. PubMed ID: 10718486
[TBL] [Abstract][Full Text] [Related]
20. Haploinsufficiency for p190B RhoGAP inhibits MMTV-Neu tumor progression.
Heckman-Stoddard BM; Vargo-Gogola T; McHenry PR; Jiang V; Herrick MP; Hilsenbeck SG; Settleman J; Rosen JM
Breast Cancer Res; 2009; 11(4):R61. PubMed ID: 19703301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
